Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth in vitro and in vivo. 2011

Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
Department of General Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

BACKGROUND The human coagulation trigger tissue factor (TF) is overexpressed in several types of cancer and involved in tumor growth, vascularization, and metastasis. To explore the role of TF in biological processes of lung adenocarcinoma, we used RNA interference (RNAi) technology to silence TF in a lung adenocarcinoma cell line A549 with high-level expression of TF and evaluate its antitumor effects in vitro and in vivo. METHODS The specific small interfering RNA (siRNA) designed for targeting human TF was transfected into A549 cells. The expression of TF was detected by reverse transcription-PCR and Western blot. Cell proliferation was measured by MTT and clonogenic assays. Cell apoptosis was assessed by flow cytometry. The metastatic potential of A549 cells was determined by wound healing, the mobility and Matrigel invasion assays. Expressions of PI3K/Akt, Erk1/2, VEGF and MMP-2/-9 in transfected cells were detected by Western blot. In vivo, the effect of TF-siRNA on the growth of A549 lung adenocarcinoma xenografts in nude mice was investigated. RESULTS TF -siRNA significantly reduced the expression of TF in the mRNA and protein levels. The down-regulation of TF in A549 cells resulted in the suppression of cell proliferation, invasion and metastasis and induced cell apoptosis in dose-dependent manner. Erk MAPK, PI3K/Akt pathways as well as VEGF and MMP-2/-9 expressions were inhibited in TF-siRNA transfected cells. Moreover, intratumoral injection of siRNA targeting TF suppressed the tumor growth of A549 cells in vivo model of lung adenocarcinoma. CONCLUSIONS Down-regulation of TF using siRNA could provide a potential approach for gene therapy against lung adenocarcinoma, and the antitumor effects may be associated with inhibition of Erk MAPK, PI3K/Akt pathways.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077192 Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. Lung Adenocarcinoma,Adenocarcinoma, Lung,Adenocarcinomas, Lung,Lung Adenocarcinomas
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013925 Thromboplastin Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation. Antigens, CD142,CD142 Antigens,Coagulation Factor III,Factor III,Tissue Factor,Tissue Thromboplastin,Blood Coagulation Factor III,Coagulin,Glomerular Procoagulant Activity,Prothrombinase,Tissue Factor Procoagulant,Urothromboplastin,Activity, Glomerular Procoagulant,Factor III, Coagulation,Procoagulant Activity, Glomerular,Procoagulant, Tissue Factor,Thromboplastin, Tissue

Related Publications

Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
August 2010, Journal of cancer research and clinical oncology,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
August 2009, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
May 2009, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
August 2012, Journal of cancer research and clinical oncology,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
August 2005, Cancer gene therapy,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
February 2008, Molecular cancer,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
January 2013, Journal of ophthalmology,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
June 2011, International journal of oncology,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
July 2012, Oncology reports,
Chengcheng Xu, and Qi Gui, and Wenshu Chen, and Leiming Wu, and Wei Sun, and Ni Zhang, and Qinzi Xu, and Jianing Wang, and Xiangning Fu
September 2013, Journal of translational medicine,
Copied contents to your clipboard!